DUBLIN--(BUSINESS WIRE)--The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2020" report has been added to ResearchAndMarkets.com's offering.
This report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
- Trends in royalty rates in the biopharma industry since 2010
- Analysis of royalty rate clause structure
- Case studies of real-life licensing deals which disclose royalty rates
- Comprehensive listing of licensing deals which disclose royalty rates since 2010
- Access to licensing contract documents which disclose royalty rates
- The leading licensing deals by royalty rate value since 2010
- Most active royalty rate disclosures since 2010
The report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2020. Also, it provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010.
- Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.
- Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.
- Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.
- Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.
- Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise royalty rates granted?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
- 3D Medicines
- Abbott Laboratories
- Abbvie
- Ablynx
- Abraxis BioScience
- Acceleron Pharma
- Acerus
- Actavis (acquired by Watson)
- Active Biomaterials
- Acura Pharmaceuticals
- Adamis Pharmaceuticals
- Adaptimmune
- Adeona Pharmaceuticals
- Adlai Nortye
- Aduro BioTech
- Advanced Dosage Forms
- Advaxis
- Advirna
- Aegerion Pharmaceutical
- AEterna Zentaris
- Afritex Medical Products
- Agenus Bio
- Agios Pharmaceuticals
- AIT Therapeutics
- Akcea Therapeutics
- Akebia Therapeutics
- Alchemia
- Alder Biopharmaceuticals
- Alector
- Alexion Pharmaceuticals
- Alexza Pharmaceuticals
- Alfasigma
- Alfa Wassermann
- Allergan
- Allergan (name changed from Actavis)
- Almirall
- Alnylam Pharmaceuticals
- Alternavida
- Altman Enterprises
- AltrazealTrading
- Amarantus BioSciences
- American Type Culture Collection (ATCC)
- Amgen
- Amherst Pharmaceuticals
- Amorfix Life Sciences
- Ampio Pharmaceuticals
- Amylin Pharmaceuticals
- Amyris
- AnaBios
- AnGes MG
- AnnaMed
- Antibe Therapeutics
- Antigen Express
- Apricus Biosciences
- Aquestive Therapeutics
- Aradigm
- Aratana Therapeutics
- Arch Pharmalabs
- Ardelyx
- Arena Pharmaceuticals
- Assembly Biosciences
- Astellas Pharma
- Astellas Pharma Europe
- Asterias Biotherapeutics
- AstraZeneca
- Athenex
- Atossa Genetics
- Audeo Oncology
- Aurigene Discovery Technologies
- Authentic Brands Group
- AVEO Oncology
- Avita Medical
- Avivagen
- Axovant Sciences
- Aytu BioScience
- Azaya Therapeutics
- Azure Biotech
- Baker Brothers Investments
- BASF
- Baxter International
- Bayer Healthcare
- Bayer Innovation
- Baylor Research Institute
- Belgian Volition
- Bellerophon Therapeutics
- Benitec Biopharma
- Besins Healthcare
- Beth Israel Deaconess Medical Center
- BIND Biosciences
- BioCorRx
- BioCryst Pharmaceuticals
- Bioeq IP
- Biogen
- BioGene Technology
- BioInvent
- BiolineRX
- BioMarin Pharmaceutical
- BioNovion
- BioNTech
- Biopharmex
- BiopharmX
-
and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/9cdllk
